A Phase 1/2, Open-label, Multi-center Study to Assess the Safety and Tolerability of Durvalumab (Anti-PDL1 Antibody) as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocitic Leukemia

Trial Profile

A Phase 1/2, Open-label, Multi-center Study to Assess the Safety and Tolerability of Durvalumab (Anti-PDL1 Antibody) as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocitic Leukemia

Suspended
Phase of Trial: Phase I/II

Latest Information Update: 25 Sep 2017

At a glance

  • Drugs Durvalumab (Primary) ; Bendamustine; Ibrutinib; Lenalidomide; Rituximab
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms FUSION NHL 001
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 07 Sep 2017 According to a Celgene Corporation media release, the US FDA has placed a partial clinical hold on this trial, based on risks identified in other trials for an anti-PD-1 agent, pembrolizumab, in patients with multiple myeloma in combination with immunomodulatory agents.
    • 07 Sep 2017 Status changed from recruiting to suspended, according to a Celgene Corporation media release.
    • 29 Aug 2017 Planned number of patients changed from 253 to 265.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top